Medline Inc.
MDLN
Positions held
Your positionsMDLN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Medline Inc. is positioned in a growing healthcare industry, with increasing demand for medical instruments and supplies.
- Revenue increased by 5% compared to the prior quarter, reaching $7.7 billion.
- Gross margin improved to 28.8%, up from 25% in the previous quarter.
- The company has a high trailing P/E ratio of 88.875, indicating potential overvaluation.
- Net income decreased to $60 million in Q2 2026 from $129 million in Q1 2026.
- Operating margin remains low at 5.1%, reflecting challenges in profitability.
Fundamentals
| Market cap | $48.09B | Enterprise value | $48.80B | Trailing P/E | 89.35 | Forward P/E | 22.67 |
| PEG | — | Price / book | 2.71 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 11.6% | Earnings growth | 262.0% | Gross margin | 25.1% | Operating margin | 0.8% |
| Profit margin | 2.3% | ROE | 4.9% | ROA | 2.5% | Debt / equity | 0.66 |
| Current ratio | 4.33 | Free cash flow | $850.63M | Analyst recommendation | buy | Mean target | $44.42 |
| 52w high | $50.88 | 52w low | $31.49 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $7.7B | $7.4B | $7.8B | — | — | $6.6B |
| Op margin | 5.1% | 5.7% | 5.5% | — | — | 8.6% |
| Net income | $60.0M | $129M | $182M | — | — | $322M |
| Gross margin | 28.8% | 25.0% | 24.6% | — | — | 27.5% |
| Gross profit | $2.2B | $1.8B | $1.9B | — | — | $1.8B |
| Operating income | $395M | $422M | $425M | — | — | $571M |
- Revenue +5% vs prior quarter ($7.7B vs $7.4B).
- Gross margin 28.8% (was 25% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $28.4B | — | — | — |
| Op margin | 7.8% | — | — | — |
| Net income | $1.2B | — | — | — |
| Gross margin | 26.4% | — | — | — |
| Gross profit | $7.5B | — | — | — |
| Operating income | $2.2B | — | — | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Medline to report third quarter 2026 results on November 4, 2026
2026-09-25 · UBS Cuts Medline Price Target to $43 From $45, Maintains Buy Rating
2026-09-24 · Astellas lists 431K sf Northbrook HQ in possible sale-leaseback play
2026-09-20 · Medline (MDLN) Could Be 29% Undervalued As Its Pullback Tests Sentiment
2026-09-19 · Medline (MDLN) Stock Could Trade Below Fair Value As Shares Fell 22%
2026-09-16 · Medline (MDLN) Slips Amid Broader MedTech Weakness
2026-09-10 · Jim Cramer Names Medline (MDLN) a Sleeper Compounder
2026-09-04 · Artisan Sold Medline (MDLN) as Cost Pressures Delayed the Company’s Profit Recovery
2026-09-03 · Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
2026-08-14 · Tigress Financial Adjusts Medline Price Target to $55 From $62, Maintains Buy Rating
2026-08-12 · Medline (MDLN) Q2 2026 Earnings Call Transcript
Price (daily)
Full chart · RSI · MACD · patterns